Law360, New York (September 21, 2009) -- A class of indirect purchasers has requested final approval of a proposed allocation plan for a $65.7 million settlement of a consolidated action accusing Abbott Laboratories and Fournier Industrie et Sante of blocking generic competition for the cholesterol drug TriCor.
Two-thirds of the settlement amount would be distributed among both individuals and entities in the U.S. who purchased fenofibrate products, sold by Abbott under the brand name TriCor, between April...
